ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$2.06 USD
-0.08 (-3.74%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $2.06 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.06 USD
-0.08 (-3.74%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $2.06 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Zacks News
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
by Zacks Equity Research
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
by Zacks Equity Research
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for ALX Oncology Holdings (ALXO) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
by Zacks Equity Research
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
by Zacks Equity Research
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
by Zacks Equity Research
Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
by Zacks Equity Research
Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
by Zacks Equity Research
Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.
ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
ALX Oncology Holdings Inc. (ALXO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
ALX Oncology Holdings Inc. (ALXO) Loses -18.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for ALX Oncology Holdings Inc. (ALXO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Merck (MRK) Q2 Earnings & Revenues Top, COVID Drug Helps Sales
by Zacks Equity Research
Merck (MRK) beats on Q2 estimates for earnings and sales. The company continues to see robust growth in COVID drug sales and Keytruda and Gardasil sales.
Alkermes' (ALKS) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Alkermes (ALKS) beat estimates for both earnings and sales in the second quarter of 2022. The company narrows sales guidance for Vivitrol and Aristada. Stock down.
ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC
by Zacks Equity Research
The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.
New Strong Sell Stocks for January 19th
by Zacks Equity Research
ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022
ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
ALX Oncology Holdings Inc. (ALXO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
ALX Oncology (ALXO) has been struggling lately, but the selling pressure may be coming to an end soon.
Why Earnings Season Could Be Great for ALX Oncology (ALXO)
by Zacks Equity Research
ALX Oncology (ALXO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.